NewsPrismaUS, UK, Canada & Australia news, compared across the papers
LIVE
Business

Amplia gets nod for new cancer drug trial ahead of US push

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Covered by 2 sources from Australia. First reported by The Sydney Morning Herald ·

How 2 newspapers cover this story

  1. The Sydney Morning HeraldAustraliaFirst report

    Amplia gets nod for new cancer drug trial ahead of US push

    Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

  2. The AgeAustralia

    Amplia gets nod for new cancer drug trial ahead of US push

    Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Coverage details

2 outlets from Australia are covering this story: The Sydney Morning Herald and The Age. The Sydney Morning Herald and The Age published it almost at the same time, on November 19, 2026.

Key names in the coverage: Amplia Therapeutics and ACCENT-Mini.

More news from November 19, 2026 →

Related stories